amg 162

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Bone Metastases in Men With Hormone-Refractory Prostate Cancer

Conditions

Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

Trial Timeline

Jul 1, 2009 → Apr 1, 2012

NCT ID

NCT00950911

About amg 162

amg 162 is a phase 3 stage product being developed by Amgen for Bone Metastases in Men With Hormone-Refractory Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00950911. Target conditions include Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00950911	Phase 3	Completed	Jul 1, 2009	Apr 1, 2012	Bone Metastases in Men With Hormone-Refractory Prostate Cancer
NCT00325468	Phase 3	Completed	May 1, 2006	Aug 2, 2012	Low Bone Mineral Density

Competing Products

20 competing products in Bone Metastases in Men With Hormone-Refractory Prostate Cancer

See all competitors

Product	Company	Stage	Hype Score
Denosumab + Zoledronic Acid	Daiichi Sankyo	Phase 3	77
Enzalutamide	Astellas Pharma	Phase 2	52
Enzalutamide	Astellas Pharma	Phase 2	52
Tacrolimus	Astellas Pharma	Phase 2	52
Tacrolimus	Astellas Pharma	Phase 2	52
Merestinib	Eli Lilly	Phase 1	33
FORTEO + Placebo	Eli Lilly	Phase 1	33
Arzoxifene + Placebo	Eli Lilly	Phase 3	77
Tanezumab	Eli Lilly	Phase 3	77
Anastrozole + Tamoxifen	AstraZeneca	Phase 3	77
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements	Novartis	Phase 3	77
Zoledronic acid	Novartis	Phase 3	77
Zoledronic acid + Letrozole	Novartis	Phase 3	77
Zoledronic acid	Novartis	Phase 3	77
Nilotinib	Novartis	Phase 1	33
Reclast (ZOL446, zoledronic acid)	Novartis	Approved	85
Zoledronic acid	Novartis	Phase 3	77
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid	Novartis	Phase 3	77
zoledronic acid	Novartis	Phase 1	33
Ruxolitinib continuous therapy	Novartis	Phase 2	52

Other Products from Amgen